Women's Health studies
A prospective cohort analysis of atypical femur fractures (AFF) in women from Kaiser Permanente Southern California (KPSC): identification of risk factors and construction of risk prediction models
The goals of this study are to develop multivariate risk prediction models to predict the 2-year risk of atypical femur fractures and 2-year risk of hip fracture. A secondary goal is to create a simple clinical tool that will allow clinicians and patients to estimate the risk of both types of fractures.
An Intervention Study of Reminder Letter for Gardasil Regimen Completion
The goal of this randomized intervention study is to evaluate the effectiveness of a quarterly mailing intervention on human papillomavirus vaccine three-dose regimen completion.
Antidepressants and Breast Cancer Pharmacoepidemiology
This study examines drug interactions between tamoxifen and antidepressants in nearly 23,000 breast cancer survivors diagnosed with early stage disease in the two largest health plans in California.
Boostrix immunization in pregnant women
The goal of the Boostrix study is to examine pre-specified pregnancy-related adverse events in a cohort of women vaccinated with Boostrix at 27 weeks gestation or beyond compared to a matched historical unvaccinated control group.
Impact of Bariatric Surgery on Cancer Incidence in Severely Obese Adults
The goal of this project is to estimate the impact of bariatric surgery versus routine non-surgical care on the incidence of cancer (all types) in all severely obese patients (men and women).
Incidence and trend of ectopic pregnancy 2008-2017: a population-based study
Examining the recent trends in ectopic pregnancy among women of childbearing ages.
Principal Investigator:Darios Getahun, MD, PhD, MPH
Funding Source:Bayer Pharmaceuticals Corporation
Funding Years:2018 - 2019
Research Categories:Women's Health
Menveo Pregnancy Registry Study
The objective of the Menveo Pregnancy Registry is to evaluate pregnancy outcomes among women immunized with the Menveo vaccine within 28 days prior to conception or at any time during pregnancy. The primary outcomes of interest include major congenital malformation, preterm birth, and low birth weight. Other pregnancy outcomes will be collected, including spontaneous abortions and stillbirths.
Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment
Evaluating the effect of treating mild-to-moderate hypertension in pregnancy, compare the risks of clinically important outcomes with different medications, and determine whether the benefits and risks vary by maternal race/ethnicity or obesity status.
Sleep Inflammation and Depression Occurrence in Breast Cancer Survivors (STRIVE1)
The aim of this prospective study is to examine the association between sleep disturbance, cellular and genomic markers of inflammation, and depression occurrence in breast cancer survivors.
The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Follow-up Study
The HAPO Follow-up Study will recruit from the cohort of women and their offspring who participated in the original HAPO Study to test the hypothesis that hyperglycemia in pregnancy, less severe than overt diabetes, is independently associated with increased risk of adverse childhood and maternal outcomes 8-12 years later. The general aim of the study is to obtain measures of adiposity, glucose, insulin sensitivity and secretion, lipids, inflammation and blood pressure in 7,000 HAPO mother-offspring (aged 8-12) pairs of multiple ethnic/race groups from ten of the original HAPO field centers. (RO1DK061628)
Site Principal Investigator:Jean M. Lawrence, ScD, MPH, MSSA
Funding Source:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Funding Years:2012 - 2017
Use of Multiple Biomarkers with the Risk of Ovarian Cancer Algorithm (ROCA) for Early Detection of Ovarian Cancer in Female Carriers of BRCA1 and BRCA2 mutations
The goal of this prospective recruitment study is to determine if ovarian cancer screening is enhanced by more frequent biomarker testing (CA125 & HE4) versus usual testing frequency in women with BRCA1/2 mutations.